India, July 31 -- Werewolf Therapeutics (HOWL) on Friday reported a net profit for the second quarter ended June 30, 2026, driven by significant gains from a collaboration revenue. Company Profile Werewolf Therapeutics is a clinical-stage biopharmaceutical company focused on developing conditionally activated therapeutics that stimulate the immune system for the treatment of cancer. Its pipeline includes WTX-124, an IL-2 INDUKINE molecule, and WTX-330, an IL-12 INDUKINE molecule, for advanced or metastatic solid tumors. Second Quarter Results The company reported net profit of $3.67 million, or $0.08 per share, compared with a net loss of $17.98 million, or $0.40 per share, in the prior-year second quarter. Collaboration revenue totaled $21...